Johnson & Johnson releases fourth-quarter fiscal 2025 results on Wednesday, January 21, before the market opens. Analysts project earnings per share will climb 22% to around $2.49-$2.50, while revenue should grow 7.3% year-over-year to approximately $24.14 billion.
Johnson & Johnson, JNJ
The stock has been on fire. JNJ shares rocketed 47-48.7% over the past 12 months, obliterating the S&P 500’s 14.7% advance.
Wall Street analysts show mixed feelings heading into the report. Seven rate the stock a Buy while five recommend Hold, according to TipRanks. The average price target of $221.09 implies only 1.1% upside from current levels.
The Dividend King maintains its impressive payout streak. JNJ has increased dividends for over 60 consecutive years and currently pays $1.30 per share quarterly, yielding 2.50%.
The Innovative Medicine segment should power Q4 results. Darzalex, Tremfya, and Erleada are expected to post strong numbers. Analysts forecast Darzalex sales at $3.74 billion, Tremfya at $1.36 billion, and Erleada at $936 million.
Newer launches are picking up steam. Carvykti, Tecvayli, Talvey, Rybrevant, Caplyta, Lazcluze, and Spravato should all contribute to growth.
But Stelara is getting crushed. Multiple biosimilar versions hit the U.S. market in 2025 from Amgen, Teva, Samsung Bioepis/Sandoz, and others. The loss of exclusivity hammered the Innovative Medicines segment by 1,070 basis points in Q3. Analysts expect the damage to accelerate in Q4 as more biosimilars enter the market. Stelara sales are pegged at just $1.36 billion.
Imbruvica faces its own challenges from oral competitors and Medicare Part D redesign impacts. Estimates stand at $670 million. Generic competition for Zytiga and Remicade continues nibbling away at sales.
The MedTech business has bounced back in recent quarters. Cardiovascular acquisitions Abiomed and Shockwave are performing well. Surgery, Vision, and electrophysiology products are gaining traction. Consensus estimates peg MedTech revenue at $8.71 billion.
China remains problematic. The government’s volume-based procurement program keeps squeezing MedTech margins through forced price cuts.
JNJ dropped positive Caplyta data on January 16. Phase 3 trials showed the drug boosted remission rates in major depressive disorder when combined with antidepressants. After six months, 65% of patients achieved remission. The FDA approved Caplyta for this use in November 2025.
The company cut a deal with the Trump administration on drug pricing while securing tariff exemptions. It’s also moving forward with major U.S. manufacturing expansion plans totaling $55 billion. A $2 billion biologics plant in Wilson, North Carolina will create roughly 5,000 jobs.
The talc litigation headache persists. A Maryland jury hit JNJ with a $1.56 billion verdict, the biggest single-plaintiff award yet, over alleged mesothelioma from baby powder. The company insists the product never contained asbestos and will appeal the decision.
Management previously signaled consensus estimates for 2026 were too conservative. Back in October, JNJ expected revenue growth above 5% versus analyst forecasts of 4.6%. Earnings per share were projected roughly 5 cents higher than the October consensus of $11.39.
The stock trades at 19.01 times forward earnings, above the industry average of 17.73 and JNJ’s five-year mean of 15.65. The company has topped earnings expectations in each of the last four quarters with an average beat of 3.75%.
Investors will scrutinize updated 2026 guidance and management commentary on biosimilar competition, talc litigation, and pipeline progress when JNJ reports January 21.
The post Johnson & Johnson (JNJ) Stock: What to Expect From Earnings Wednesday appeared first on Blockonomi.


